Referências

1. Gärtner J, Hauser SL, Bar-Or A, et al. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Mult Scler. 2022;28(10):1562-75. 2. Bula de KESIMPTA® para profissionais. VPS7. Aprovada pela Anvisa em 17/02/2025. 3. Wiendl H, Hauser S, Nicholas J, et al. Longer-term safety and efficacy of ofatumumab in people with relapsing multiple sclerosis for up to 6 years (P9-6.010). Neurology. 2024;102(17 Suppl 1). 4. Ross AP, Besser C, Naval S, Stoneman D, Gaunt H, Barker N. Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey. BMC Neurol. 2023;23(1):85. 5. Terlizzi RD, King M, Blohm C. Usability validation of the Sensoready® pen in patients with relapsing multiple sclerosis. Ther Deliv. 2023;14(4):259–68. 6. Ministério da Saúde, Agência Nacional de Saúde. RESOLUÇÃO NORMATIVA - RN Nº 584 DE 7 DE AGOSTO DE 2023. Diário Oficial da União 151; 09/08/2023; Sec. 1:85. Acesso em: 27/01/2025. Disponível em: https://www.gov.br/ans/pt-br/arquivos/acesso-ainformacao/ participacao-da-sociedade/consultas-publicas/cp112/RN_584.pdf. 7. Hauser SL, Bar-Or A, Cohen JA, et al; ASCLEPIOS I and ASCLEPIOS II trial groups. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546-57. 8. Cohen JA, Hauser SL, Cross AH, et al. Five-year safety of ofatumumab in people living with relapsing multiple sclerosis. P8-004. Apresentado no: 75th American Academy of Neurology Annual Meeting; 22-27 de abril de 2023; Boston, Massachusetts, EUA.